News Story: Full Text
Sponsored By
Gamma Tiles
Please Click On The Above Banner For More Details
Braintumor Website


Tumor Treating Fields Utilization in a Glioblastoma Patient with a Preexisting Cardiac Pacemaker: The First Reported Case.

Al's Comment:

 At least we now know you do not have to physically remove the pacemaker to use Optune.  Unfortunately you still have to turn it off. 

Hopefully there will be more testing done so that we can keep it turned on.

Posted on: 08/01/2018

Send to
World Neurosurg. 2018 Jul 28. pii: S1878-8750(18)31640-1. doi: 10.1016/j.wneu.2018.07.162. [Epub ahead of print]
Tumor Treating Fields Utilization in a Glioblastoma Patient with a Preexisting Cardiac Pacemaker: The First Reported Case.
McClelland S 3rd1, Henrikson CA2, Ciporen JN3, Jaboin JJ4, Mitin T4.
Author information
Tumor treating fields (TTF) have become an important, evidence-based modality in the treatment of glioblastoma (GBM). In patients requiring cardiac pacemakers, TTF therapy is complicated by theoretical concerns regarding possible electrical interaction between the devices.
A 57-year-old man with past medical history of sick sinus syndrome requiring cardiac pacemaker implantation suffered an acute neurologic change associated with a left parieto-occipital lesion, which was found to be GBM. After completion of guideline-concordant chemoradiation, he chose to undergo TTF therapy. Because of the absence of cardiac symptoms and the theoretical risk of far-field sensing by the pacemaker of the TTF device (potentially resulting in pacemaker inhibition), the pacemaker was turned off prior to receiving TTF. Following TTF implementation, the patient responded well; he remains alive more than 25 months following his GBM diagnosis, exceeding the median 20.9 month survival of the recently completed phase III TTF randomized clinical trial for newly diagnosed GBM. Furthermore, he has exhibited neither cardiac morbidity nor adverse scalp reactions to TTF therapy.
The first reported case of successful TTF administration in a GBM patient with a previously implanted cardiac pacemaker may allay the concerns of neuro-oncologists, cardiologists, radiation oncologists, and all certified TTF prescribers regarding the applicability of TTF in suitable candidates with preexisting cardiac pacemakers. This case indicates that TTF therapy may be efficacious in patients with indwelling MRI-conditional cardiac pacemakers turned to the off position, and that physical removal of the pacemaker is not necessary prior to starting TTF.
Copyright © 2018 Elsevier Inc. All rights reserved.
Cardiac Pacemaker; Glioblastoma; Tumor Treating Fields
PMID: 30064027 DOI: 10.1016/j.wneu.2018.07.162


Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557